Keliximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Keliximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (primate/human)
Target CD4
Clinical data
Legal status
?
Routes intravenous
Identifiers
CAS number 174722-30-6 N
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]

References[edit]

  1. ^ Kon, OM; Sihra, BS; Compton, CH; Leonard, TB; Kay, AB; Barnes, NC (1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587. 
  2. ^ WHO Drug Information